Harer et al., 2021 - Google Patents
Novel Coronavirus disease 2019 (COVID-19) Current update: perspective on epidemiology, diagnosis, drug Targets and vaccinesHarer et al., 2021
View PDF- Document ID
- 7112125503037329837
- Author
- Harer S
- Sonar P
- Publication year
- Publication venue
- Coronaviruses
External Links
Snippet
Background: A novel coronavirus disease, 2019-nCoV (COVID-19), was reported first in Wuhan, the capital of Hubei, China, in late December 2019 and subsequently reached pandemic level affecting around 213 countries. As of 24th May 2020, the total number of …
- 229960005486 vaccines 0 title abstract description 51
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahn et al. | Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19) | |
| Pillay | Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein | |
| Hofmann et al. | Cellular entry of the SARS coronavirus | |
| Glowacka et al. | Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response | |
| Focosi et al. | Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy | |
| Qian et al. | Identification of the receptor-binding domain of the spike glycoprotein of human betacoronavirus HKU1 | |
| Park et al. | Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses | |
| Kumavath et al. | The spike of SARS-CoV-2: uniqueness and applications | |
| Dominguez et al. | Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses | |
| Mahalingam et al. | Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing | |
| Catanzaro et al. | ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses | |
| Eggink et al. | Phenotypic effects of substitutions within the receptor binding site of highly pathogenic avian influenza H5N1 virus observed during human infection | |
| Ma et al. | Dual-fluorescence labeling pseudovirus for real-time imaging of single SARS-CoV-2 entry in respiratory epithelial cells | |
| Li et al. | SARS-CoV-2 virology | |
| Escalera et al. | SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage | |
| Kaur et al. | COVID-19 infection: epidemiology, virology, clinical features, diagnosis and pharmacological treatment | |
| Zhang et al. | The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies | |
| Roessler et al. | Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test | |
| Septisetyani et al. | SARS-CoV-2 antibody neutralization assay platforms based on epitopes sources: live virus, pseudovirus, and recombinant S glycoprotein RBD | |
| Zahn et al. | Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19 | |
| Ren et al. | Characterization of SARS-CoV-2 variants B. 1.617. 1 (Kappa), B. 1.617. 2 (Delta) and B. 1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor | |
| Harer et al. | Novel Coronavirus disease 2019 (COVID-19) Current update: perspective on epidemiology, diagnosis, drug Targets and vaccines | |
| Vincenzi et al. | The Fight against Human Viruses: How NMR Can Help? | |
| Bhavaniramya et al. | Comprehensive analysis of SARS-COV-2 drug targets and pharmacological aspects in treating the COVID-19 | |
| Vashisht et al. | Exploring the immunodominant epitopes of SARS-CoV-2 nucleocapsid protein as exposure biomarker |